Literature DB >> 2579347

Role of plasmin, thrombin, and antithrombin III as etiological factors in delayed cerebral vasospasm.

R P White, J T Robertson.   

Abstract

The fibrinolytic enzyme plasmin at 0.25 units/ml produced a contraction of isolated canine basilar arteries that developed slowly and was sustained for at least 2 hours. Plasmin and thrombin (1 unit/ml) acted synergistically to enhance the contractile response. In contrast to plasmin, the marked contraction elicited by thrombin ended within 1 hour, and afterward the artery was completely tachyphylactic to thrombin. Fibrin clot, fibrinopeptides, and fibrin degradation products did not prolong significantly the effect of thrombin or prevent the tachyphylaxis. Plasmin and thrombin may occupy a common membrane receptor because exposing the artery briefly to trypsin (24 micrograms/ml) thereafter abolished the contractile effect of plasmin and thrombin without affecting the action of other agonists. Antithrombin III (1.0 unit/ml) relaxed basilar arteries that were precontracted with plasmin (0.5 unit/ml), thrombin (1.0 unit/ml), serotonin (10(-5) M), uridine triphosphate (10(-4) M), or KCl (8 X 10(-2) M). The results suggest that the vasoconstrictor effect of thrombin might contribute to hemostasis after subarachnoid hemorrhage (SAH) but, because of tachyphylaxis, not to delayed vasospasm. On the other hand, the constrictor action of plasmin might appear late in the course of SAH in association with clot lysis and tissue repair. Last, the level of the vasorelaxant antithrombin III in cerebrospinal fluid could control the appearance and severity of cerebral arterial spasm in SAH.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579347

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  8 in total

1.  Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid haemorrhage.

Authors:  Katsuharu Kameda; Yuichiro Kikkawa; Mayumi Hirano; Satoshi Matsuo; Tomio Sasaki; Katsuya Hirano
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

2.  Blood-arterial wall barrier disruption to various sized tracers following subarachnoid haemorrhage.

Authors:  T Nakagomi; N F Kassell; H Johshita; R M Lehman; S Fujiwara; T Sasaki
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

3.  Cisternal and lumbar CSF levels of arachidonate metabolites after subarachnoid haemorrhage: an assessment of the biochemical hypothesis of vasospasm.

Authors:  R Rodriguez y Baena; P Gaetani; V Silvani; T Viganò; M T Crivellari; P Paoletti
Journal:  Acta Neurochir (Wien)       Date:  1987       Impact factor: 2.216

Review 4.  Role of thrombin in CNS damage associated with intracerebral haemorrhage: opportunity for pharmacological intervention?

Authors:  Hideki Matsuoka; Rikuzo Hamada
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

5.  Cerebrovascular effects of substance P after experimental subarachnoid haemorrhage.

Authors:  A Pasqualin; T Tsukahara; K Hongo; O Van Beek; N F Kassell; J C Torner
Journal:  Acta Neurochir (Wien)       Date:  1992       Impact factor: 2.216

6.  Prostaglandin D2 monitoring in human CSF after subarachnoid hemorrhage: the possible role of prostaglandin D2 in the genesis of cerebral vasospasm.

Authors:  P Gaetani; V Silvani; M T Crivellari; T Viganò; R Rodriguez y Baena; P Paoletti
Journal:  Ital J Neurol Sci       Date:  1986-02

Review 7.  When the Blood Hits Your Brain: The Neurotoxicity of Extravasated Blood.

Authors:  Jesse A Stokum; Gregory J Cannarsa; Aaron P Wessell; Phelan Shea; Nicole Wenger; J Marc Simard
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

Review 8.  Secondary White Matter Injury and Therapeutic Targets After Subarachnoid Hemorrhage.

Authors:  Xufang Ru; Ling Gao; Jiru Zhou; Qiang Li; Shilun Zuo; Yujie Chen; Zhi Liu; Hua Feng
Journal:  Front Neurol       Date:  2021-07-15       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.